New drug combo tested for Tough-to-Treat liver cancers
NCT ID NCT03092895
Summary
This study tested the safety and effectiveness of a new immunotherapy drug called SHR-1210 when given with other cancer drugs. It involved 157 people with advanced liver cancer or bile duct cancer who had either tried previous treatments or were newly diagnosed. The main goal was to see if the drug combinations were safe and if they could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
81 Hospital Nanjing
Nanjing, Jiangsu, 210002, China
-
Cancer Hospital of Henan province
Zhengzhou, Henan, 450008, China
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
-
Hunan Cancer Hospital
Hunan, Changsha, 410000, China
-
The First Affiliated Hospital of Nanchang University
Jiangxi, Nanchang, 330006, China
-
The Second Affiliated Hospital Of Anhui Medical University
Hefei, Anhui, 230000, China
-
Zhongshan Hospital
Shanghai, Shanghai Municipality, 200003, China
Conditions
Explore the condition pages connected to this study.